Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model.

ABSTRACT: Incretin mimetics are frequently used in the treatment of type 2 diabetes because they potentiate β cell response to glucose. Clinical evidence showing short-term benefits of such therapeutics (e.g., liraglutide) is abundant; however, there have been several recent reports of unexpected complications in association with incretin mimetic therapy. Importantly, clinical evidence on the potential effects of such agents on the β cell and islet function during long-term, multiyear use remains lacking. We now show that prolonged daily liraglutide treatment of >200 days in humanized mice, transplanted with human pancreatic islets in the anterior chamber of the eye, is associated with compromised release of human insulin and deranged overall glucose homeostasis. These findings raise concern about t

SUBMITTER: Abdulreda MH 

PROVIDER: S-EPMC4785083 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature